September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Treatment of Acute Zonal Occult Outer Retinopathy
Author Affiliations & Notes
  • Alexander Barnes
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Angela Bessette
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Careen Y Lowder
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Sunil K Srivastava
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Alexander Barnes, None; Angela Bessette, None; Careen Lowder, Allergan (C), Xoma (C); Sunil Srivastava, Allergan (C), Allergan (F), Bausch and Lomb (C), Bioptigen (P), Clearside (C), Clearside (F), Novartis (F), Optos (C), Regeneron (C), Sanofi (C), Santen (C), Synergetics (P), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1879. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexander Barnes, Angela Bessette, Careen Y Lowder, Sunil K Srivastava; Treatment of Acute Zonal Occult Outer Retinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1879.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To report on the use of systemic and intravitreal steroids as part of the treatment for acute zonal occult outer retinopathy (AZOOR).

Methods : Retrospective, interventional case series of 12 eyes of 6 patients with AZOOR who received oral prednisone or oral prednisone plus intravitreal steroid (triamcinolone acetonide (IVTA, 2 mg/0.05 mL), dexamethasone (Ozurdex) implant, and/or fluocinolone (Retisert) implant. Patients were evaluated with visual acuity, intraocular pressure, and multimodal imaging. The duration of follow-up ranged from 7 to 65 months.

Results : 4 women and 2 men were included. The mean age at presentation was 53.5 years (range 36-72 years). All patients presented acutely/sub-acutely with photopsia and/or scotoma and were treated with oral prednisone. 4 patients also received treatment to cover for possible infectious etiologies while on high-dose prednisone. 9/12 eyes were treated subsequently with intravitreal steroids. 2 eyes received IVTA followed by Ozurdex, 1 eye received IVTA followed by Retisert, 2 eyes received IVTA alone, 3 eyes received Ozurdex alone, and 1 eye received Ozurdex followed by IVTA. Visual acuity remained stable or improved in 9 eyes. Visual acuity declined from 20/15 to 20/20 at final follow-up in both eyes of 1 patient. One eye declined from 20/30 to 20/40 in the setting of a subfoveal choroidal neovascular membrane which developed during the treatment course and was managed with serial intravitreal bevacizumab injections. All patients were stable off of systemic immunosuppression at final follow-up except one patient who remained on methotrexate and azathioprine. CellCept (mycophenolate mofetil) was discontinued after Retisert placement in one patient. Adverse events in eyes treated with intravitreal steroid included visually-significant cataract (1/10 phakic eyes) and increased intraocular pressure (5/12 eyes) that was controlled with topical medications. Among all eyes, IOP ranged from 10-28 mmHg, with an overall average increase of 2 mmHg between initial encounter and final follow-up.

Conclusions : Systemic and intravitreal steroids were effective in achieving disease stability in patients with AZOOR and were generally well-tolerated. Intraocular pressure must be monitored closely in patients treated with intravitreal steroids.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.